RxDoctor Payments Data

Vikas Bhatia, MD

Cardiovascular Disease · St Petersburg, FLNPI 1265661532

Payments from drug & device makers

$1,534in general payments, 2019–2025

Across 36 payments — averaging $42.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$273
  • Abbott$217
  • Medtronic$209
  • Shockwave Medical, Inc$207
  • Ancora Heart, Inc.$140
  • AstraZeneca$133
  • plus $355 from 5 others

What the payments were for

  • Food & beverage$1,534100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,534 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$521,180
Medicare patients
1,780
Services billed
4,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban434$419,300
XareltoRivaroxaban98$106,077
FarxigaDapagliflozin Propanediol26$24,456
Repatha SureclickEvolocumab14$9,600
Dabigatran EtexilateDabigatran Etexilate Mesylate18$3,424
Metoprolol Succinate252$3,325
Atorvastatin Calcium195$1,498
Isosorbide Mononitrate ErIsosorbide Mononitrate92$1,393
Losartan Potassium183$1,244
Rosuvastatin Calcium72$1,213
Nifedipine ErNifedipine26$1,123
Bumetanide22$1,092
Metoprolol Tartrate168$1,025
ClopidogrelClopidogrel Bisulfate87$948
Nitroglycerin61$888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$133$24,45626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →